336 related articles for article (PubMed ID: 24727987)
41. ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy.
Rosell R; Karachaliou N; Wolf J; Ou SH
Lancet Respir Med; 2014 Dec; 2(12):966-8. PubMed ID: 25466349
[No Abstract] [Full Text] [Related]
42. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
Loong HH; Mok K; Leung LK; Mok TS
Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
[TBL] [Abstract][Full Text] [Related]
43. Targeting epidermal growth factor receptor in the management of lung cancer.
Mok TS; Lee K; Leung L
Semin Oncol; 2014 Feb; 41(1):101-9. PubMed ID: 24565584
[TBL] [Abstract][Full Text] [Related]
44. Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.
Koga T; Suda K; Mitsudomi T
Cancer Sci; 2022 Mar; 113(3):815-827. PubMed ID: 34997674
[TBL] [Abstract][Full Text] [Related]
45. Successes and limitations of targeted cancer therapy in breast cancer.
Curigliano G; Criscitiello C
Prog Tumor Res; 2014; 41():15-35. PubMed ID: 24727984
[TBL] [Abstract][Full Text] [Related]
46. Anticancer drug resistance: An update and perspective.
Nussinov R; Tsai CJ; Jang H
Drug Resist Updat; 2021 Dec; 59():100796. PubMed ID: 34953682
[TBL] [Abstract][Full Text] [Related]
47. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
Kris MG; Johnson BE; Berry LD; Kwiatkowski DJ; Iafrate AJ; Wistuba II; Varella-Garcia M; Franklin WA; Aronson SL; Su PF; Shyr Y; Camidge DR; Sequist LV; Glisson BS; Khuri FR; Garon EB; Pao W; Rudin C; Schiller J; Haura EB; Socinski M; Shirai K; Chen H; Giaccone G; Ladanyi M; Kugler K; Minna JD; Bunn PA
JAMA; 2014 May; 311(19):1998-2006. PubMed ID: 24846037
[TBL] [Abstract][Full Text] [Related]
48. Clinical efficacy and possible applications of genomics in lung cancer.
Alharbi KK
Asian Pac J Cancer Prev; 2015; 16(5):1693-8. PubMed ID: 25773789
[TBL] [Abstract][Full Text] [Related]
49. Epigenetics in Personalized Management of Lung Cancer.
Ahmad A
Adv Exp Med Biol; 2016; 890():111-22. PubMed ID: 26703801
[TBL] [Abstract][Full Text] [Related]
50. Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities.
Yoda S; Dagogo-Jack I; Hata AN
Pharmacol Ther; 2019 Jan; 193():20-30. PubMed ID: 30121320
[TBL] [Abstract][Full Text] [Related]
51. Gene aberrations for precision medicine against lung adenocarcinoma.
Saito M; Shiraishi K; Kunitoh H; Takenoshita S; Yokota J; Kohno T
Cancer Sci; 2016 Jun; 107(6):713-20. PubMed ID: 27027665
[TBL] [Abstract][Full Text] [Related]
52. Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations.
König D; Savic Prince S; Rothschild SI
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33671873
[TBL] [Abstract][Full Text] [Related]
53. The evolving genomic classification of lung cancer.
Shames DS; Wistuba II
J Pathol; 2014 Jan; 232(2):121-33. PubMed ID: 24114583
[TBL] [Abstract][Full Text] [Related]
54. Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives.
Ferrara MG; Di Noia V; D'Argento E; Vita E; Damiano P; Cannella A; Ribelli M; Pilotto S; Milella M; Tortora G; Bria E
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32397295
[TBL] [Abstract][Full Text] [Related]
55. Emerging oncogenic fusions other than
Suda K; Mitsudomi T
Transl Lung Cancer Res; 2020 Dec; 9(6):2618-2628. PubMed ID: 33489822
[TBL] [Abstract][Full Text] [Related]
56. Oncogenic alterations in advanced NSCLC: a molecular super-highway.
Friedlaender A; Perol M; Banna GL; Parikh K; Addeo A
Biomark Res; 2024 Feb; 12(1):24. PubMed ID: 38347643
[TBL] [Abstract][Full Text] [Related]
57. Predictive biomarkers in precision medicine and drug development against lung cancer.
Fang B; Mehran RJ; Heymach JV; Swisher SG
Chin J Cancer; 2015 Jul; 34(7):295-309. PubMed ID: 26134262
[TBL] [Abstract][Full Text] [Related]
58. [Targeted therapy in thyroid cancer: Towards a treatment card].
Lkhoyaali S; Benhmida S; Ait Elhaj M; Layachi M; Bensouda Y; Errihani H
Pathol Biol (Paris); 2015 Feb; 63(1):1-6. PubMed ID: 25555494
[TBL] [Abstract][Full Text] [Related]
59. Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance.
Schram AM; Chang MT; Jonsson P; Drilon A
Nat Rev Clin Oncol; 2017 Dec; 14(12):735-748. PubMed ID: 28857077
[TBL] [Abstract][Full Text] [Related]
60. KRAS AND THE REALITY OF PERSONALIZED MEDICINE IN NON-SMALL CELL LUNG CANCER.
Kilgoz HO; Bender G; Scandura JM; Viale A; Taneri B
Mol Med; 2016 Sep; 22():380-387. PubMed ID: 27447490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
